Evidence map›Paper›PMID 22674009›Full record

ArticleCancer2012

Receptor-interacting protein (RIP) and Sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis.

Pachiyappan Kamarajan, Turki Y Alhazzazi, Theodora Danciu, Nisha J D'silva, Eric Verdin, Yvonne L Kapila

Open access · bronzeAbstract read
In one paragraph

Article in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Regulation of anoikis by extrinsic death receptor pathways.Cell communication and signaling : CCS · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Mitochondrial sirtuin 3 and various cell death modalities.Frontiers in cell and developmental biology · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Necrostatin-1 Alleviates Bleomycin-Induced Pulmonary Fibrosis and Extracellular Matrix Expression in Interstitial Pulmonary Fibrosis.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  14. Article
  15. Review
  16. Sirtuins Expression and Their Role in Retinal Diseases.Oxidative medicine and cellular longevity · 2017
    Review
  17. Modeling head and neck cancer stem cell-mediated tumorigenesis.Cellular and molecular life sciences : CMLS · 2016
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pachiyappan KamarajanDepartment of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, Michigan 48109-1078, USA.
Turki Y Alhazzazi
Theodora Danciu
Nisha J D'silva
Eric Verdin
Yvonne L Kapila
University of Michigan–Ann Arbor · USUniversity of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
FIBRONECTIN REGULATION OF CARCINOMA APOPTOSISR01DE014429 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAPILA, YVONNE L · 2004 to 2009
$1.3M
Fibronectin Regulation of AnoikisR56DE014429 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KAPILA, YVONNE L · 2010 to 2010
$367k
NIAID NIH HHS P30 AI027763NIDCR NIH HHS R01 DE014429NIDCR NIH HHS R01DE014429NIDCR NIH HHS R56 DE014429NIDCR NIH HHS R56DE014429
6 · The paper itself

Abstract

backgroundRegulating cross-talk between anoikis and survival signaling pathways is crucial to regulating tissue processes and mitigating diseases like cancer. Previously, the authors demonstrated that anoikis activates a signaling pathway involving the CD95/Fas-mediated signaling pathway that is regulated by receptor-interacting protein (RIP), a kinase that shuttles between Fas-mediated cell death and integrin/focal adhesion kinase (FAK)-mediated survival pathways. Because it is known that sirtuin-3 (SIRT3), a nicotinamide adenine dinucleotide-dependent deacetylase, regulates cell survival, metabolism, and tumorigenesis, the authors hypothesized that SIRT3 may engage in cross-talk with Fas/RIP/integrin/FAK survival-death pathways in cancer cell systems.

methodsUsing immunohistochemical staining, immunoblotting, human tissue microarrays, and overexpression and suppression approaches in vitro and in vivo, the roles of RIP and SIRT3 were examined in oral squamous cell carcinoma (OSCC) anoikis resistance and tumorigenesis.

resultsRIP and SIRT3 had opposite expression profiles in OSCC cells and tissues. Stable suppression of RIP enhanced SIRT3 levels, whereas stable suppression of SIRT3 did not impact RIP levels in OSCC cells. The authors observed that, as OSCC cells became anoikis-resistant, they formed multicellular aggregates or oraspheres in suspension conditions, and their expression of SIRT3 increased as their RIP expression decreased. Also, anoikis-resistant OSCC cells with higher SIRT3 and low RIP expression induced an increased tumor burden and incidence in mice, unlike their adherent OSCC cell counterparts. Furthermore, stable suppression of SIRT3 inhibited anoikis resistance and reduced tumor incidence.

conclusionsThe current results indicted that RIP is a likely upstream, negative regulator of SIRT3 in anoikis resistance, and an anoikis-resistant orasphere phenotype defined by higher SIRT3 and low RIP expression contributes to a more aggressive phenotype in OSCC development.

Indexed as

AnoikisAdultAgedCarcinoma, Squamous CellCell Line, TumorFemaleHumansMaleMiddle AgedMouth NeoplasmsReceptor-Interacting Protein Serine-Threonine KinasesSirtuin 3Receptor-Interacting Protein Serine-Threonine KinasesSIRT3 protein, humanSirtuin 3

Identifiers

PMID22674009
PMCPMC3443499
OpenAlexW2072973105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.